newsmetry
rusign inget started
macro

Piramal Pharma H1 FY27 revenue rises 23%, EBITDA margin up over 350 bps

Piramal Pharma reported 23% revenue growth in H1 FY27 and an EBITDA margin gain of over 350 bps, led by its CDMO and CHG segments, per TradingView.

published on Newsmetry
original source published

the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →

Newsmetry newsroom

what happened

Piramal Pharma reported 23% revenue growth for the first half of fiscal 2027 (H1 FY27). Its EBITDA margin expanded by more than 350 basis points. The CDMO segment led with 28% growth, the CHG business grew 24%, and Consumer Healthcare rose 14%.

Management said the second half is typically stronger than the first and pointed to a healthy order book. The details come from a TradingView report that cites the company's press release, distributed via PR Newswire.

why it matters

For markets this looks more like confirmation of improving growth and margins than a surprise. The key next step will be concrete guidance for the second half and how quickly orders convert into revenue.

tags

EarningsStockIndia

instruments

PPLPHARMA

sources

  1. Piramal Pharma Limited (PPLPHARMA) Posts H1 FY27 Revenue Up 23%, EBITDA Margin +350 bps — TradingView, 27 October 2026 at 19:23 UTC
  2. Piramal Pharma Limited (PPLPHARMA) H1 Revenue Up 23%, Margin +350 bps — TradingView, 27 October 2026 at 19:28 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.

get stories in real time ↗

related stories